Answers are grounded in this paper and cite their sources.
Summary. An electroimmunoassay with a precipitating rabbit anti‐human factor IX antiserum and an inhibitor neutralization assay with a non‐precipitating homologous antibody were used to measure factor IX antigen (IX:Ag) in 117 patients from 98 kindreds with haemophilia B; and to investigate in a mixed population the incidence of different immunological types of the disease. Although the two assays showed an excellent correlation, the electroimmunoassay was selected for its simplicity as a criterion for classification. 52 kindreds, referred to as haemophilia B‐, were characterized by severe deficiency of factor IX coagulant activity (<0.01‐0.03 u/ml) and unmeasurable IX:Ag (< 0.12 u/ml): this genetic variant of the disease appears to be related to a complete or marked suppression of factor IX synthesis. In 16 kindreds, a severe or moderately severe IX:C deficiency was associated with normal or increased levels of IX:Ag (haemophilia B+): among them, a subgroup of five kindreds could be identified by the additional abnormality of a prolonged Thrombotest clotting time (haemophilia BM). These patients are likely to be the expression of normal or increased synthesis of a factor IX molecule markedly defective in the site(s) responsible for coagulant activity. Reduced levels of IX:Ag (0.12‐0.65 u/ml) characterized the remaining 30 kindreds, presenting with IX: C levels ranging from < 0.01 to 0.21 u/ml. In 28 there was a significant excess of IX:Ag over IX:C, suggesting a reduced capacity to synthesize the factor IX molecule accompanied by a variable defect in the coagulant site; the remaining two kindreds, which showed a concomitant reduction of IX:C and IX:Ag, are likely to be examples of a true reduction of factor IX synthesis.
No takes yet. Share an insight, caveat, or question.
Parekh et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: